Targeting increased levels of APP in Down syndrome: Posiphen‐mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model

OBJECTIVE: Recent clinical trials targeting amyloid beta (Aβ) and tau in Alzheimer's disease (AD) have yet to demonstrate efficacy. Reviewing the hypotheses for AD pathogenesis and defining possible links between them may enhance insights into both upstream initiating events and downstream mech...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xu‐Qiao, Salehi, Ahmad, Pearn, Matthew L., Overk, Cassia, Nguyen, Phuong D., Kleschevnikov, Alexander M., Maccecchini, Maria, Mobley, William C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Theoretical Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984396/
https://www.ncbi.nlm.nih.gov/pubmed/32975365
http://dx.doi.org/10.1002/alz.12185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984396/
https://www.ncbi.nlm.nih.gov/pubmed/32975365
http://dx.doi.org/10.1002/alz.12185

Ejemplares similares